The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-Raf(V600E) kinase.
Ren, L., Ahrendt, K.A., Grina, J., Laird, E.R., Buckmelter, A.J., Hansen, J.D., Newhouse, B., Moreno, D., Wenglowsky, S., Dinkel, V., Gloor, S.L., Hastings, G., Rana, S., Rasor, K., Risom, T., Sturgis, H.L., Voegtli, W.C., Mathieu, S.(2012) Bioorg Med Chem Lett 22: 3387-3391
- PubMed: 22534450 
- DOI: https://doi.org/10.1016/j.bmcl.2012.04.015
- Primary Citation of Related Structures:  
4E4X - PubMed Abstract: 
Herein we describe the discovery of a novel series of ATP competitive B-Raf inhibitors via structure based drug design (SBDD). These pyridopyrimidin-7-one based inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. Optimization led to the identification of compound 17, a potent, selective and orally available agent with excellent pharmacokinetic properties and robust tumor growth inhibition in xenograft studies ...